Avidity Biosciences Files Proxy Statement

TL;DR

AVDX proxy filing out, no fee. Standard shareholder comms.

AI Summary

Avidity Biosciences, Inc. filed a DEFA14A proxy statement on October 28, 2025, related to soliciting materials under Rule 14a-12. The filing indicates no fee was required for this submission. Avidity Biosciences, Inc. is a pharmaceutical preparations company incorporated in Delaware with its principal office in San Diego, California.

Why It Matters

This filing is a routine proxy statement, indicating the company is engaging in shareholder communication and potentially seeking votes or approvals on corporate matters.

Risk Assessment

Risk Level: low — This is a standard proxy filing (DEFA14A) which typically contains routine corporate information and does not inherently signal significant new risks.

Key Players & Entities

• Avidity Biosciences, Inc. (company) — Registrant
• 0001193125-25-252215 (filing_id) — Accession Number
• 20251028 (date) — Filing Date
• 3020 CALLAN ROAD, SAN DIEGO, CA 92121 (address) — Business Address

FAQ

Key Financial Figures

• $0.001 — hares of SpinCo Common Stock, par value $0.001 per share (" SpinCo Common Stock "), at
• $0.0001 — er 10 shares of common stock, par value $0.0001 per share, of the Company, with SpinCo

Filing Documents

• d852122ddefa14a.htm (DEFA14A) — 53KB
• g852122g1028060940069.jpg (GRAPHIC) — 4KB
• 0001193125-25-252215.txt ( ) — 59KB

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding the proposed acquisition of Avidity and Avidity's related Spin-Off, the expected timetable for completing each of the proposed Transactions, the composition of the assets and liabilities to be held by SpinCo and Avidity following the Spin-Off, the management team for SpinCo and its cash balance, potential marketing approvals, new indications or labeling for Avidity's product candidates, Avidity's platform and preclinical assets, or potential future revenues from Avidity's product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are forward-looking statements. There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time, or that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value. There can be no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all or that the expected benefits or synergies from the Transactions will be achieved in the expected

Forward-Looking Statements

Forward-Looking Statements This communication contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding the proposed acquisition of Avidity and Avidity's related spin-off, the expected timetable for completing each of the proposed Transactions, the composition of the assets and liabilities to be held by SpinCo and Avidity following the spin-off, the management team for SpinCo and its cash balance, potential marketing approvals, new indications or labeling for Avidity's product candidates, Avidity's platform and preclinical assets, or potential future revenues from Avidity's product candidates. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Avidity's investigational products will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time, or that Avidity's approach to the discovery and development of product candidates based on its AOC platform will produce any products of commercial value. There can be no guarantee that the conditions to the closing of the Transactions will be satisfied on the expected timetable or at all or that the expected benefits or synergies from the Transactions will be achieved in the expected ti

View Full Filing

View this DEFA14A filing on SEC EDGAR